Wright Medical Group (FRA:WM3) Debt-to-Equity : 2.65 (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Wright Medical Group Debt-to-Equity?

Wright Medical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2015 was €0.6 Mil. Wright Medical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2015 was €498.1 Mil. Wright Medical Group's Total Stockholders Equity for the quarter that ended in Jun. 2015 was €188.2 Mil. Wright Medical Group's debt to equity for the quarter that ended in Jun. 2015 was 2.65.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Wright Medical Group's Debt-to-Equity or its related term are showing as below:

FRA:WM3' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: 2.65

FRA:WM3's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs FRA:WM3: 2.65

Wright Medical Group Debt-to-Equity Historical Data

The historical data trend for Wright Medical Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wright Medical Group Debt-to-Equity Chart

Wright Medical Group Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Debt-to-Equity

Get a 7-Day Free Trial

0.43

0.37

0.49

0.60

1.01

Wright Medical Group Quarterly Data
	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15
Debt-to-Equity	Get a 7-Day Free Trial															0.64	0.74	1.01	2.22	2.65

Competitive Comparison of Wright Medical Group's Debt-to-Equity

For the Medical Devices subindustry, Wright Medical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wright Medical Group's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Wright Medical Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Wright Medical Group's Debt-to-Equity falls into.

Wright Medical Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Wright Medical Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2014 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.582	+	227.576)	/	226.109
	=	1.01

Wright Medical Group's Debt to Equity Ratio for the quarter that ended in Jun. 2015 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.609	+	498.089)	/	188.162
	=	2.65

Wright Medical Group (FRA:WM3) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Wright Medical Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Wright Medical Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Wright Medical Group (FRA:WM3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Wright Medical Group Inc (FRA:WM3) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.wmt.com

Wright Medical Group Inc, through Wright Medical Technology, Inc. and other operating subsidiaries, is a specialty orthopaedic company, that provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients' lifestyles. The Company provides surgical solutions for the foot and ankle market and markets its products in over 60 countries. Its business includes products that are used in foot and ankle repair, upper extremity products, and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and their patients. Extremity hardware includes implants and other devices to replace or reconstruct injured or diseased joints and bones of the foot, ankle, hand, wrist, fingers, toes, elbow and shoulder, which it generally refer to as either foot and ankle or upper extremity products. The Company's manufacturing and warehousing operations are located in Arlington, Tennessee. Outside the U.S., The Company has distribution and administrative facilities in Amsterdam, the Netherlands, and sales and distribution offices in Canada, Australia, and Europe. The Company operates its continuing operations as one reportable segment and offer products in extremity reconstruction and biologics. The Company's products include CHARLOTTE, CLAW II, DARCO, EVOLVE, MICRONAIL, GRAFTJACKET, OSTEOSET. Its competitors include major companies in the orthopaedic and biologics industries, as well as academic institutions and other public and private research organizations that continue to conduct research, seek patent protection and establish arrangements for commercializing products. The Company's products are strictly regulated by the FDA under the Food, Drug, and Cosmetic Act. Some of its products are also regulated by state agencies.

Wright Medical Group (FRA:WM3) Headlines

No Headlines